Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Saladax Biomedical, a pharmacodiagnostic company, has reported that Myriad Genetics, a biopharmaceutical company, has developed and launched its seventh molecular diagnostic product, OnDose, which utilizes patent rights licensed from Saladax.
Subscribe to our email newsletter
According to Saladax, OnDose provides a quantitative measure in blood of exposure of the patient to 5-Fluorouracil (5-FU), providing oncologists with a routinely available tool for personalizing infusion chemotherapy drug dosing to help optimize clinical efficacy and reduce toxic side effects.
Myriad has obtained from Saladax an exclusive North American license of patents arising from pioneering discoveries by Saladax. Under the terms of the patent license, Myriad has exclusive rights to develop, manufacture, sell and distribute products developed by Myriad for 5-FU in the US and Canada. OnDose is being sold through Myriad’s 150-person oncology sales force.
Salvatore Salamone, CEO of Saladax said: “We are very pleased that Myriad’s development of a test based on licensed rights from Saladax’ discoveries has resulted in a product now available to the US oncology community. This is a win-win situation for all involved – Myriad, Saladax, doctors, payers, and most importantly, cancer patients.”